第六节 防控策略
人感染禽流感的防控是当前公共卫生面临的巨大挑战。在我国,人感染禽流感防控的难点主要包括:①自然环境中的病毒分布广泛且病毒在自然宿主中持续发生变异,导致新的AIV不断出现,一旦病毒发生宿主适应性变异,则可导致人感染。②国内禽类规模化养殖模式发展仍不充分,农村地区仍然存在大量散养禽类,特别是在临水地区,水禽放养模式增加了病毒从野生水禽向家禽传播并最终导致人感染的机会。③国内的禽类消费模式以及市场等环境中禽类高度聚集、消毒等卫生处理不足导致病毒暴露风险增加。④禽类的跨地区运输增加了病毒的远距离传播风险。⑤人群对新出现病毒的普遍缺乏免疫保护等。
接种疫苗是控制人感染禽流感的重要手段。但除美国FDA批准供应急使用的H5N1疫苗外,目前尚没有人用H5N1和H7N9禽流感疫苗可供使用。禽类接种疫苗可有效降低禽间病毒感染,大幅降低病毒感染造成的禽类大量死亡,减少经济损失;同时大幅降低禽类病毒携带率,有效降低禽类接触人员者的感染。2016—2017年,由于人感染H7N9亚型AI病例大幅增加,以及高致病性H7N9亚型AIV的出现造成禽类大量死亡,导致2017年我国在禽间强制推广疫苗接种,使用的疫苗成分为经反向遗传技术制备的重组禽流感(H5/H7)3价灭活疫苗(Re-11/Re-12/Re-2),包括Clade 2.3.2.1(Re-11)和Clade 2.3.4.4(Re-12)两种H5亚型以及H7亚型(Re-2)抗原成分。监测发现,自疫苗使用以来,包括市场在内的环境中H7亚型AIV的检出大幅下降,人感染H7N9亚型AI病例也得到了有效遏制。但禽类疫苗接种推动了病毒的进化,对家禽养殖业和公共安全仍构成潜在威胁。
由于禽类在人感染AI传播流行中具有重要的作用,因此每当新型AIV出现并导致禽或人大量感染时,短期大量扑杀禽类往往是疫情应急处置的重要手段,特别是没有特异性疫苗可供使用情况下,禽类扑杀能够起到立竿见影的效果。然而禽类扑杀将严重损害养殖户经济利益,损害禽类养殖业发展。因此,在禽间或人间开展病原学监测,及时发现新型AIV并评估其传播风险,以及及时更新疫苗是避免发生新型AIV传播流行的重要手段。
目前我国已经建立了较为完善的禽间AIV监测网络,但人感染AI的监测尚有不足,因此需进一步加强人感染AI病例及病原学监测工作。此外,定期开展活禽市场清洗、消毒和休市措施,有利于改善市场环境卫生,减少人群暴露风险;同时,开展人群健康教育,改变公众禽类消费模式等措施也有利于人感染禽流感的防控。
(翁育伟)
参考文献
[1]Lycett SJ,Duchatel F,Digard P.A brief history of bird flu[J].Philos Trans R Soc Lond B Biol Sci,2019,24,374 (1775) :20180257.DOI :10.1098/rstb.2018.0257.
[2]Rongbao Gao,Bin Cao,Yunwen Hu,et al.Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus[J].N Engl J Med,2013,16;368 (20) :1888-1897.DOI :10.1056/NEJMoa1304459.
[3]Suttie A ,Deng Y M,Greenhill A R,et al.Inventory of molecular markers affecting biological characteristics of avian influenza A viruses[J].Virus Genes,2019,55 (6) :739-768.DOI :10.1007/s11262-019-01700-z.
[4]Xu Y,Peng R,Zhang W,et al.Avian to Human Receptor Binding Adaptation of Avian H7N9 Influenza Virus Hemagglutinin[J].Cell Rep,2019,19;29 (8) :2217-2228.DOI :10.1016/j.celrep.2019.10.047.
[5]Nilsson B E,Te Velthuis A J W,Fodor E.Role of the PB2 627 domain in influenza A virus polymerase function[J].J Virol,2017,91 (7) :e02467-16.DOI :10.1128/JVI.02467-16.
[6]Shi J Z,Deng G,Kong H,et al.H7N9 virulent mutants detected in chickens in China pose an increased threat to humans[J].Cell Res,2017,27 (12) :1409-1421.DOI :10.1038/cr.2017.129.
[7]Duan L,Bahl J,Smith GJ,et al.The development and genetic diversity of H5N1 influenza virus in China,1996-2006[J].Virology.2008,380 (2) :243-254.DOI :10.1016/j.virol.2008.07.038.
[8]Di Liu,Weifeng Shi,Yi Shi,et al.Origin and diversity of novel avian influenza A H7N9 viruses causing human infection:phylogenetic,structural,and coalescent analyses[J].Lancet,2013,381 (9881) :1926-1932.DOI:org/10.1016/S0140-6736 (13) 60938-1.
[9]Lunbiao Cui,Di Liu,Weifeng Shi,et al.Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9) virus[J].Nat Commun,2014,5:3142.DOI :10.1038/ncomms4142.(https://www.daowen.com)
[10]Shengjie Lai,Ying Qin,Benjamin J Cowling,et al.Global epidemiology of avian influenza A H5N1 virus infection in humans,1997–2015:a systematic review of individual case data[J].Lancet Infect Dis,2016.,16 (7) :e108-e118.DOI :10.1016/S1473-3099 (16) 00153-5.
[11]Tanner WD,Toth DJ,Gundlapalli AV,et al.The pandemic potential of avian influenza A (H7N9) virus:a review[J].Epidemiol Infect,2015,143 (16) :3359-3374.DOI :10.1017/S0950268815001570.
[12]Debby van Riel,Vincent J Munster,Emmie de Wit,et al.H5N1 virus attachment to lower respiratory tract[J].Science,2006,312 (5772) :399.DOI :10.1126/science.1125548.
[13]Debby van Riel,Lonneke M E Leijten,Miranda de Graaf,et al.Novel Avian-Origin Influenza A (H7N9) Virus Attaches to Epithelium in Both Upper and Lower Respiratory Tract of Humans[J].Am J Pathol,2013,183 (4) :1137-1143.DOI :10.1016/j.ajpath.2013.06.011.
[14]Satoshi Fukuyama,Yoshihiro Kawaoka.The pathogenesis of influenza virus infections:the contributions of virus and host factors[J].Curr Opin Immunol,2011,23 (4) :481-6.DOI :10.1016/j.coi.2011.07.016.
[15]Liu Q,Zhou Y H,Yang Z Q.The cytokine storm of severe influenza and development of immunomodulatory therapy[J].Cell Mol Immunol,2016,13 (1) :3-10.DOI :10.1038/cmi.2015.74.
[16]Menno D de Jong,Cameron P Simmons,Tran Tan Thanh,et al.Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia[J].Nat Med,2006,12 (10) :1203-1207.DOI :10.1038/nm1477.
[17]Christine Korteweg,Jiang Gu.Pathology,Molecular Biology,and Pathogenesis of Avian Influenza A (H5N1) Infection in Humans[J].Am J Pathol,2008,172 (5) :1155-1170.DOI:10.2353/ajpath.2008.070791.
[18]Yufeng Liu,Hongpan Xu,Chang Liu,et al.CRISPR-Cas13a Nanomachine based simple technology for Avian Influenza A (H7N9) Virus on-site detection[J].J Biomed Nanotechnol,2019,15 (4) :790-798.DOI :10.1166/jbn.2019.2742
[19]Amitava Moulick,Lukas Richtera,Vedran Milosavljevic,et al.Advanced nanotechnologies in avian influenza:Current status and future trends-A review[J].Analytica Chimica Acta,2017,983:42-53.DOI:org/10.1016/j.aca.2017.06.045
[20]Hongjie Yu,Zhancheng Gao,Zijian Feng,et al.Clinical Characteristics of 26 Human Cases of Highly Pathogenic Avian Influenza A (H5N1) virus infection in China[J].PLoS One,2008,3 (8) :e2985.DOI :10.1371/journal.pone.0002985.
[21]Hai-Nv Gao,Hong-Zhou Lu,Bin Cao,et al.Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection[J].N Engl J Med,2013,368 (24) :2277-2285.DOI :10.1056/NEJMoa1305584.
[22] Behzadi MA.,Leyva-Grado VH.Overview of Current Therapeutics and novel candidates against influenza,respiratory syncytial virus,and middle east respiratory syndrome coronavirus infections[J].Front Microbiol,2019,10:1327.DOI :10.3389/fmicb.2019.01327.
[23]Boping Zhou,Nanshan Zhong,Yi Guan.Treatment with Convalescent Plasma for Influenza A (H5N1) Infection[J].N Engl J Med,2007,357 (14) :1450-1451.DOI :10.1056/NEJMc070359
[24]David S Hui,Nelson Lee,Paul K Chan,et al.The role of adjuvant immunomodulatory agents for treatment of severe influenza.Antiviral Res[J].2018,150:202-216.DOI :10.1016/j.antiviral.2018.01.002.